Which sub populations are more at-risk for cognitive decline and fast disease progression?
The Richman Family Precision Medicine Center of Excellence in Alzheimer’s Disease (AD) is a unique translational project aimed at characterizing a finite set of therapeutically relevant AD subtypes taking into account known genetic factors, biologic “endophenotypes” assessed by blood, cerebrospinal fluid (CSF), or brain imaging, as well as aspects of clinical phenotype.
The ultimate goal is to translate this knowledge into clinical care by defining patients who respond optimally to currently available and emerging therapies. Subtyping will also lead to identifying new therapeutic targets based on refined and granular understanding of disease mechanisms.
Alzheimer's and Dementia Research
Questions we're asking that inform us on how to best care for patients include:
Big Data Power
Scaling Evidenced-Based Care
How can the current quality care be made available to all persons with dementia throughout Johns Hopkins?
Closing the Loop
Innovation - Brain Scans
Innovation - New Blood Test
Innovation - Stem Cell Models
Patient Care for Alzheimer's Disease
The research we do directly impacts the treatment options available to our patients. Find out more about patient care for Alzheimer's Disease.
The Johns Hopkins Memory and Alzheimer's Treatment Center
The Johns Hopkins Bayview Medical Center
5300 Alpha Commons Drive, Floor 4
Baltimore, MD 21224
Dimitrios Kapogiannis, M.D. is Chief of the Human Neuroscience Unit at the National Institute of Aging and adjunct Associate Professor in the Department of Neurology at Johns Hopkins. He is a clinician-scientist, ABPN-certified in Neurology and UCNS-certified in Behavioral Neurology. His translational laboratory focuses on discovering novel biomarkers for preclinical diagnosis and therapeutic response in Alzheimer's and other neurodegenerative diseases. He has pioneered deriving Extracellular Vesicles enriched for neuronal and astrocytic origin from peripheral blood.